凯洛斯制药（KAPA.A）股价单日暴涨77%至1.21美元，逼近五个月高位。若涨幅维持，将创近六个月最佳单日表现。公司宣布其实验性癌症疗法ENV-105在晚期前列腺癌中期研究中展现良好耐受性。
该疗法与标准激素治疗药物阿帕他胺联合用于转移性去势抵抗性前列腺癌（mCRPC）患者治疗。这类患者肿瘤在激素阻断治疗下仍持续进展。公司预计将于九月公布该试验的中期疗效数据。
市场交投异常活跃，当日成交量突破1.82亿股，达到25日均量的154倍。尽管今日大涨，该股年内迄今累计跌幅仍达20%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.